*Cystectomy Humans Prospective Studies Systematic Reviews as Topic Treatment Outcome Urinary Bladder/pathology/surgery *Urinary Bladder Neoplasms/pathology/surgery models mortality nomograms radical cystectomy urinary bladder neoplasms

Humans Administration Intravesical Antibiotics Antineoplastic/administration & dosage Hematuria/drug therapy *Mitomycin/administration & dosage Prospective Studies Quality of Life Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology/surgery

*Carcinoma Transitional Cell/pathology/surgery Combined Modality Therapy Consensus Humans Neoplasm Invasiveness/pathology Quality of Life Urinary Bladder/pathology/surgery *Urinary Bladder Neoplasms/drug therapy/surgery Bladder neoplasms Bladder preservation Expert consensus Multi-disciplinary treatment

Cystectomy/methods Humans Learning Curve Postoperative Complications/etiology/surgery *Robotic Surgical Procedures/methods *Robotics Treatment Outcome *Urinary Bladder Neoplasms/surgery bladder cancer cystectomy systematic review

Blood Loss Surgical/statistics & numerical data Blood Transfusion/statistics & numerical data Cystectomy/*methods Female Humans Male Neoplasm Invasiveness Postoperative Complications/epidemiology/etiology Robotic Surgical Procedures/*methods Treatment Outcome Urinary Bladder Neoplasms/pathology/*surgery Urinary Diversion/adverse effects/*methods Ecud Extracorporeal urinary diversion Icud Intracorporeal urinary diversion Rarc

Cystectomy/adverse effects/*methods Humans Treatment Outcome Urethra Urinary Bladder Neoplasms/*surgery Bipolar Monopolar Systematic review Turbt

bladder cancer incidence meta-analyses metformin treatment outcome commercial or financial relationships that could be construed as a potential conflict of interest.

Cystectomy/*methods Electrosurgery/*methods Humans Neoplasm Invasiveness Treatment Outcome Urethra Urinary Bladder Neoplasms/pathology/*surgery Bipolar Meta-analysis Monopolar Transurethral bladder tumor resection

Humans *Laser Therapy/adverse effects Neoplasm Invasiveness Treatment Outcome Urinary Bladder Neoplasms/pathology/*surgery

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/pathology Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Humans Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Immune checkpoint inhibitors Platinum-based chemotherapy Survival outcomes Treatment guidelines Urothelial carcinoma funded this work. MK PK and SD are employees of Evidera.

Disease-Free Survival *Dose Fractionation Radiation Humans Neoplasm Recurrence Local/epidemiology/pathology/*radiotherapy Radiation Dose Hypofractionation/*standards Risk Factors Treatment Outcome Urinary Bladder Neoplasms/epidemiology/pathology/*radiotherapy

*Clinical Protocols *Cystectomy/methods *Enhanced Recovery After Surgery Humans Time Factors Treatment Outcome Urinary Bladder Neoplasms/*surgery Cystectomy Eras Fast track Meta-analysis Protocol Systematic review evidence-based medicine

Carcinoma Transitional Cell/*classification/*genetics/mortality Humans Predictive Value of Tests Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*classification/*genetics/mortality Bladder cancer Molecular classification Molecular subtype Prognosis Progression Urothelial carcinoma

Carcinoma in Situ/*diagnosis/*therapy Humans Treatment Outcome Urinary Bladder Neoplasms/*diagnosis/*therapy Bladder cancer Carcinoma in situ Non–muscle-invasive bladder cancer

Adjuvants Immunologic/*administration & dosage Administration Intravesical BCG Vaccine/*administration & dosage Humans *Lymphocytes Tumor-Infiltrating Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/immunology/*pathology

Adjuvants Immunologic/therapeutic use BCG Vaccine/therapeutic use Evidence-Based Medicine Humans Neoplasm Invasiveness Neoplasm Recurrence Local/*therapy Treatment Outcome Urinary Bladder Neoplasms/pathology/*therapy Bacillus Calmette-Guerin unresponsive Bladder preservation therapy Bladder sparing Non–muscle-invasive bladder cancer

Aged Cystectomy/adverse effects/*methods/statistics & numerical data Humans Male Middle Aged Postoperative Complications Quality of Life Randomized Controlled Trials as Topic Robotic Surgical Procedures/adverse effects/*methods/statistics & numerical data Treatment Outcome Urinary Bladder Neoplasms/*surgery

Administration Intravesical Antibiotics Antineoplastic/administration & dosage/*therapeutic use BCG Vaccine Carcinoma Transitional Cell/*drug therapy Humans Mitomycin/administration & dosage/*therapeutic use Randomized Controlled Trials as Topic Treatment Outcome Urinary Bladder Neoplasms/*drug therapy

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/immunology/mortality/pathology/*therapy Chemotherapy Adjuvant/methods/statistics & numerical data Clinical Trials Phase I as Topic Clinical Trials Phase II as Topic Cystectomy Disease-Free Survival Follow-Up Studies Humans Immune Checkpoint Inhibitors/*therapeutic use Muscle Smooth/pathology/surgery Neoadjuvant Therapy/*methods/statistics & numerical data Neoplasm Invasiveness/pathology Prospective Studies Treatment Outcome Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/immunology/mortality/pathology/*therapy Bladder cancer Immune checkpoint inhibitors Immunotherapy Neoadjuvant

Cystectomy/adverse effects Humans Postoperative Complications/diagnosis/epidemiology/etiology Risk Factors *Robotic Surgical Procedures/adverse effects *Robotics Treatment Outcome *Urinary Bladder Neoplasms/surgery Urologic Surgical Procedures *Urology Complications European Association of Urology guidelines Outcome reporting Robot-assisted radical cystectomy Standardised tool